Get the Stockscreener App
6.29
1.45%
0.09
After Hours:
6.40
0.11
+1.75%
Mannkind Corp stock is traded at $6.29, with a volume of 1.86M.
It is up +1.45% in the last 24 hours and up +0.48% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$6.20
Open:
$6.16
24h Volume:
1.86M
Relative Volume:
0.74
Market Cap:
$1.71B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
-33.11
EPS:
-0.19
Net Cash Flow:
$18.24M
1W Performance:
-3.53%
1M Performance:
+0.48%
6M Performance:
+38.85%
1Y Performance:
+52.30%
1-Day Range:
$6.14
$6.36
1-Week Range:
$6.14
$6.60
52-Week Range:
$3.17
$6.92
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind's SWOT analysis: inhaled therapeutics firm's stock shows promise amid challenges - Investing.com
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®) - GlobeNewswire Inc.
MannKind Co. (NASDAQ:MNKD) Shares Bought by Dark Forest Capital Management LP - MarketBeat
Mannkind Corp (MNKD)’s results reveal risk - US Post News
The Attractiveness of Investing In Mind Medicine Inc (MNMD) is Growing - Knox Daily
A new trading data show Mannkind Corp (MNKD) is showing positive returns. - SETE News
MNKD stock rated an Outperform by Leerink Partners - Knox Daily
Closing Figures: Mind Medicine Inc (MNMD)’s Negative Finish at 5.87, Down -1.68 - The Dwinnex
Manba Finance IPO Sees Stellar 73.18 Times Subscription on Second Day - Devdiscourse
Manba Finance IPO subscribed 73.18 times on Day 2 amid heavy demand from institutional investors - NewsDrum
Latest News - LatestLY
Mind Medicine Inc (MNMD) produces promising results - US Post News
Stock market update: Nifty Pharma index advances 0.23% - The Economic Times
Manba Finance IPO continues to attract great interest, subscribed 73 times on day 2 - Moneycontrol
Manba Finance IPO subscribed 56 times so far on Day 2 - Indiainfoline
Manba Finance IPO Day 2: Issue subscribed 41.11 times so far, check key dates and more - Upstox
Manaba Finance IPO Day 2: Check latest subscription, expected listing gains - India Today
Mankind Pharma To Raise Rs 7,000-Crore Debt For Bharat Serums Acquisition - NDTV Profit
Stock to buy today: Mankind Pharma (₹2,651.30): BUY - BusinessLine
Trade Spotlight: How should you trade Siemens, Mankind Pharma, Kotak Bank, DLF, Indegene and others on... - Moneycontrol
Avoro Capital Advisors LLC Reduces Stock Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat
Manba Finance Limited IPO Subscribed 23.67 Times on Day 1 of Bidding, Sale To Conclude on September 25; - LatestLY
Manba Finance IPO subscribed 23.67 times on Day 1 - NewsDrum
Mankind Pharma announces ₹10,000 crore fundraise | Tap to know more | Inshorts - Inshorts
Pharma stock jumps 4% after company announces ₹ 10,000 Cr fundraise - Trade Brains
Mankind Pharma Announces NCD Fundraising Initiative - Indiainfoline
Mankind Pharma Ltd soars 3.76% - Business Standard
Mankind Pharma up 4% as board approves raising Rs 10,000-cr via NCDs, CPs - Business Standard
Mankind Pharma plans to repay debt taken for BSV acquisition within three years - CNBCTV18
Mankind Pharma Shares Hit Record High After Company Announces ₹10,000 Crore Fund Raising - Free Press Journal
Mankind Pharma Shares Hit Life High After Board Nod To Rs 10,000 Crore Fundraise - NDTV Profit
Mankind Pharma jumps to record high; gains 9% in two days after Investec's 'buy' tag - Moneycontrol
Fundamentally strong pharma stocks to buy now for an upside of 30% - Trade Brains
Mankind Pharma shares surge over 2% after board approves raising Rs 10,000 crore - Business Upturn
Manba Finance Raises ₹45.25 Crore from Anchor Investors Ahead of IPO - Indiainfoline
Stocks in focus on 23rd September: HDFC Bank, Mankind Pharma, BHEL, Tata Steel and more - Business Upturn
MannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mankind Pharma board OKs to raise Rs 10,000 cr - Business Standard
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish - Insider Monkey
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish - Yahoo Finance
14 Worst 52-Week High Stocks to Buy According to Short Sellers - Insider Monkey
MNKD Shares Experience Surge in Value - Knox Daily
Mankind Pharma board approves raising Rs 10,000 crore through NCDs - The Economic Times
Riding the Waves: A Guide to Investing in MNKD Stock - The InvestChronicle
Mankind Pharma to raise up to ₹10,000 crore through NCDs - CNBCTV18
Mankind Pharma to raise funds up to Rs 10k crore via debt instruments - Business Standard
Broker’s call: Mankind Pharma (Buy) - BusinessLine
Mankind Pharma board gives nod to Rs 10,000 crore fundraise via bonds - MSN
Mankind Pharma board approves up to Rs 10,000-crore fund raise via NCDs, CPs - Moneycontrol
Mankind Pharma to raise up to Rs 10,000 crore through bonds - Zee Business
Mankind Pharma Board approves raising Rs 10,000 crore via NCDs and CPs - Business Upturn
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):